Basilea Pharmaceutica
BSLN.SW
#6351
Rank
โ‚น52.71 B
Marketcap
โ‚น4,348
Share price
2.93%
Change (1 day)
15.40%
Change (1 year)

P/E ratio for Basilea Pharmaceutica (BSLN.SW)

P/E ratio at the end of 2023: 39.9

According to Basilea Pharmaceutica's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 49.0334. At the end of 2023 the company had a P/E ratio of 39.9.

P/E ratio history for Basilea Pharmaceutica from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202339.9-17.76%
202248.6-164.35%
2021-75.596.74%
2020-38.450.15%
2019-25.560.45%
2018-15.9-67.06%
2017-48.3181.11%
2016-17.2-5.99%
2015-18.3-28.48%
2014-25.6-20.57%
2013-32.2273.67%
2012-8.6232.08%
2011-6.52-202.93%
20106.34-202.42%
2009-6.19-48.87%
2008-12.1-42.14%
2007-20.9-23.4%
2006-27.3-14.43%
2005-31.9188.64%
2004-11.1

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.